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Abstract
Background: Abacavir is one of the recommended nucleoside reverse transcriptase inhibitors (NRTIs) for the
treatment of HIV infections among children and adolescents. However, there are concerns that the antiviral
efficacy of abacavir might be low when compared to other NRTIs especially among children. There are also
concerns that abacavir use may lead to serious adverse events such as hypersensitivity reactions and has
potential predisposition to developing cardiovascular diseases
Methods: We searched four electronic databases, four conference proceedings and two clinical trial registries
in August 2014, without language restrictions. Experimental and observational studies with control groups that
examined the efficacy and safety of abacavir-containing regimens in comparison with other NRTIs as first-line
treatment for HIV-infected children and adolescents aged between one month and eighteen years were eligible. Two
authors independently screened search results, extracted data and assessed the risk of bias of included studies using a
pre-specified, standardised data extraction form and validated risk of bias tools. We also assessed the quality of
evidence per outcome with the GRADE tool.
Results: We included two randomised controlled trials (RCTs) and two analytical cohort studies with a total of
10,595 participants. Among the RCTs we detected no difference in virologic suppression after a mean duration
of 48 weeks between abacavir- and stavudine-containing regimens (2 trials; n = 326: RR 1.28; 95 % CI 0.67–2.42)
with significant heterogeneity (P = 0.02; I2 = 81 %). We also found no significant differences between the two groups
for adverse events and death. After five years of follow-up, virologic suppression improved with abacavir (1 trial; n = 69:
RR 1.96; 95 % CI 1.11–3.44). For cohort studies, we detected that the virologic suppression activity of abacavir
was less effective than stavudine in both the lopinavir/ritonavir (1 study, n = 2165: RR 0.79, 95 % CI 0.67–0.92)
and efavirenz sub-groups (1 study, n = 3204: RR 0.79, 95 % CI 0.67–0.92) respectively. The quality of evidence from
RCTs was moderate for virologic suppression but low for death and adverse events, while that of cohort studies
was low for all three these outcomes.
Conclusions: Available evidence showed little or no difference between abacavir-containing regimen and other
NRTIs regarding efficacy and safety when given to children and adolescents as a first-line antiretroviral therapy.
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Background
The acquired immunodeficiency syndrome (AIDS) remains
a major global concern with an estimated 3.3 million chil-
dren and adolescents under 15 years of age currently living
with the human immunodeficiency virus (HIV). Of these,
about 2 million need antiretroviral therapy [1–3]. In order
to effectively manage HIV infection and AIDS, it is recom-
mended that antiretroviral treatment regimens should
consist of a three-drug combination consisting of two nu-
cleoside reverse transcriptase inhibitors (NRTIs) with either
one protease inhibitor (PI) or a non-nucleoside reverse
transcriptase inhibitor (NNRTI) depending on the age of
the patient and other co-morbidities [4]. In the treatment
of children infected by HIV, abacavir is one of the recom-
mended NRTIs in children younger than 10 years of age
[4]. Abacavir, formerly known as 1592U89, is a carbocyclic
2′-deoxyguanosine nucleoside analogue with its main activ-
ity being against HIV type 1 (HIV-1). It is phosphorylated
to its active metabolite, carbovir triphosphate, which in-
hibits the HIV-1 reverse transcriptase competitively and
terminates deoxyribonucleic acid (DNA) synthesis. This
prevents HIV from replicating, thereby lowering the
amount of HIV in the body’s system [5].
The two NRTIs in a three-drug antiretroviral regimen
are referred to as the NRTI backbones of the regimen.
The World Health Organization (WHO) recommends
abacavir and either lamivudine or zidovudine as the
NRTI backbones for children younger than 3 years of
age [4]. There is a strong recommendation for the use
of these two NRTI backbones as fixed-dose combina-
tions in this paediatric age group; however, this recom-
mendation was done with a low certainty of evidence [4].
In 3- to 10-year-old children and adolescents weighing
less than 35 kg, abacavir-lamivudine is the NRTI backbone
commonly used. Again, this regimen has strong recom-
mendation for use but low certainty of evidence [4].
The WHO guidelines suggest that stavudine, a NRTI, be
replaced by abacavir because of toxicity concerns [6, 7].
However, abacavir has adverse effect concerns of its own
[8–11]. Abacavir is associated with a systemic illness
known as abacavir hypersensitivity reaction that can result
in death if the drug is not discontinued in affected
patients. This hypersensitivity may present with fever,
maculopapular rash and other constitutional symptoms
such as fatigue, malaise and myalgia. Gastrointestinal ad-
verse effects such as vomiting, diarrhoea and abdominal
pain may also occur. Occasionally, there are also some
prominent respiratory symptoms, such as tachypnea and
cough [9, 11]. Hypersensitivity reactions due to abacavir
have been reported in both paediatric and adult popula-
tions with the incidence in randomised controlled trials
ranging from 0 to 14 % [11]. HIV-infected individuals of
African descent seem to have reduced risk of abacavir
hypersensitivity [12, 13], and the wide variation in reported
adverse event incidence with abacavir use makes it neces-
sary to do a systematic review, especially in children as
there is a gap in the evidence-base. Furthermore, some
cohort studies in South Africa have shown poor virologic
responses to abacavir-based regimens when compared to
stavudine in children. These studies queried the clinical
effectiveness of abacavir when compared to the other
NRTIs as well as the justification for making it a first-line
drug in the treatment of HIV in children [14, 15]. A further
investigation on the drug is thus needed.
Some research studies suggested that abacavir increases
the risk of cardiovascular events, especially myocardial in-
farction [15, 16]. However, meta-analyses of randomised
controlled trials in adults have not supported the postula-
tion that abacavir-containing antiretroviral regimens carry
a greater risk of cardiovascular events relative to abacavir-
sparing regimens [17, 18]. Similarly, various studies
evaluating changes in inflammatory and coagulopathic
biomarkers upon commencement of abacavir-containing
regimens have produced conflicting findings [19, 20].
These randomised controlled trials were carried out
mainly on adults due to the belief that children have
lower incidence of some of these important adverse
effects of abacavir [21]. A meta-analysis of HIV infected
adults switching to abacavir-containing regimens shows
rather weak evidence of lower incidence of adverse events,
with higher incidence of virological failure in the NRTI
groups when compared to controls such as PI or NNRTI
based regimens. [22].
Despite concerns that the confidence in the currently
available evidence on the antiviral efficacy of abacavir
might be low, coupled with possible serious adverse
events such as hypersensitivity reactions and a potential
predisposition to developing cardiovascular diseases, the
WHO has recommended abacavir as one of the pre-
ferred NRTI backbones in the paediatric population [6].
We are not aware of any systematic review that assessed
the efficacy and safety of abacavir-containing regimens
in HIV infected children and adolescents.
The primary objective of this review was to assess the
antiviral efficacy of abacavir-containing combination
antiretroviral therapy (cART) regimens in comparison
with cART regimens containing other NRTIs as first-
line therapy for HIV infected children and adolescents.
The secondary objective was to assess the safety of
abacavir-containing cART antiretroviral regimens in HIV
infected children and adolescents.
Methods
This review’s protocol has been registered in the PROSPERO
International Prospective Register of systematic reviews (http://
www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD4
2014009157), registration number CRD42014009157 and
published in Systemic Reviews [23].
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Types of studies
Experimental [randomised controlled trials (RCTs) and
non-randomised controlled trials] and observational stud-
ies with control groups were eligible for inclusion in this
systematic review. Non-randomised controlled trials refer
to studies that allocated participants to interventions and
controls using alternation between groups, by the use of
birth dates or weekdays or by other non-random methods.
Types of participants
HIV infected individuals between 1 month and 18 years
of age.
Types of interventions
Experimental group: abacavir-containing cART regimens
as first-line therapy.
Control group: cART regimens containing zidovudine
or tenofovir or stavudine in the NRTI backbone as first-
line therapy.
Types of outcome measures
Primary outcomes
1. Virologic suppression. This was reported as the
proportion of participants that reached a pre-defined
concentration of HIV-1 RNA, typically <400 copies/
mL or <500 copies/mL, at 48 weeks and/or 5 years.
For purposes of meta-analysis we used the lowest
reported value.
2. Virologic failure. This was reported as the proportion
of participants who failed to suppress viral replication
to non-detectable levels.
Secondary outcomes
1. Adverse events. We defined this as the proportion of
study participants that required treatment interruption
or switching.
2. CD4 cell count. We defined this as the mean change
in the concentration of CD4 lymphocytes from
baseline, as expressed in cells/μL.
3. Hypersensitivity reaction. We defined this as abacavir
hypersensitivity reaction presenting with symptoms
such as fever, nausea, respiratory discomfort, rash and
diarrhoea.
4. Death (all cause).
5. Myocardial infarction and other cardiovascular events.
Search methods for identification of studies
Regardless of language or publication status (published,
unpublished, in press and in progress) we used a compre-
hensive search strategy to identify all relevant studies. This
was done with the support of a health science librarian at
the Faculty of Medicine and Health Sciences, Stellenbosch
University, South Africa.
Electronic databases
We searched the following electronic databases:
 MEDLINE via PubMed, on 8 August 2014
 Cochrane Central Register of Controlled Trials
(CENTRAL), on 8 August 2014
 Scopus, on 9 August 2014
 ISI Web of Science (Science Citation Index), on 9
August 2014
Based on a search strategy published by Shey et al.
[24], we used both text words and medical subject head-
ing (MeSH) terms, for example abacavir, antiretroviral,
HIV, acquired immunodeficiency syndrome, child, paedi-
atric, adolescent and randomized controlled trial to form
the basis of the search strings. We also used these terms
in different combinations and with different spellings,
and adapted them as appropriate for each database.
Additional file 1 contains the detailed search strategies.
Conference proceedings
We searched the proceedings of the following confer-
ences for potentially eligible studies on 9 August 2014:
 The European AIDS Clinical Society (EACS)
conferences
 International AIDS conferences
 Conference on Retroviruses and Opportunistic
Infections (CROI)
 International AIDS Society conference on HIV
Pathogenesis and Treatment (IAS)
We also searched for unpublished and ongoing studies
in the following prospective clinical trial registries on 11
August 2014:
 ClinicalTrials.gov (https://clinicaltrials.gov/)
 WHO International Clinical Trials Registry Platform
(http://apps.who.int/trialsearch/)
After having identified the included studies for this
review, we contacted the relevant study authors to ask if
they know of any other relevant studies in the field. We
also screened the reference lists of included studies and
relevant systematic reviews for additional studies.
Selection of studies
Two review authors OOA and TAB, independently
screened the titles and abstracts of all search outputs.
We applied pre-specified eligibility criteria to identify
potentially eligible studies. For these, we obtained the
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full text articles and again independently screened them
for final eligibility. We provided reasons for excluding
studies we viewed the full text of. Where needed, we con-
tacted the authors of potentially eligible studies to obtain
missing information or to clarify certain aspects of the
study. We resolved disagreements by discussion and
reaching consensus.
Data extraction and management
OOA and TAB independently extracted study data using
a standardised, pre-established data extraction form. We
resolved disagreements by discussion and reaching con-
sensus. For each included study, we extracted the
following:
 Study details: contact details, citation, start and end
dates, setting and design.
 Participant details: key eligibility criteria, ages,
number of participants randomised per arm, losses
to follow up, baseline HIV-1 RNA and CD4 cell
levels.
 Interventions details: names of the drugs, doses and
duration.
 Outcome details: virologic suppression, virologic
failure, adverse events, CD4 cell count,
hypersensitivity reaction to abacavir, death and
cardiovascular events.
 Miscellaneous information: funding source and
references to other relevant studies.
OOA entered the extracted data into Table 1 (Charac-
teristics of included studies) and Table 2 (Characteristics
of excluded studies).
Assessment of risk of bias in included studies
OOA and TAB independently applied the Cochrane Col-
laboration’s risk of bias tool ([25], Additional file 2) to as-
sess the methodological quality of the included RCTs. This
tool consists of seven domains, namely random sequence
generation, allocation concealment, blinding of participants
and personnel, blinding of outcome assessment, incomplete
outcome data, selective outcome reporting and other forms
of bias. We independently described our assessment for
each domain by judging them alongside explanations as
having either a ‘low risk’, ‘high risk’ of bias, or ‘unclear risk’
of bias.
To assess the methodological quality of the included
cohort studies, OOA and TAB independently applied the
Newcastle-Ottawa Scale (NOS) [26]. As per this tool, we
judged each of the included cohort studies based on three
broad categories, namely the selection of the study groups,
the comparability of the groups, and the ascertainment of
the outcome of interest. A study can be awarded a max-
imum of one star for each numbered item within the
Selection and Outcome categories, and a maximum of
two stars for the Comparability section. Detail appears in
Additional file 3.
We compared our individual judgements and resolved
discrepancies by discussion and reaching consensus.
Table 1 Characteristics of included studies
Studies Brennan 2014 [29] Musiime 2014 [28] PENTA 2002 [31, 32] Technau 2014 [14, 15]
Type of study Prospective cohort study Randomised
controlled trial
Randomised controlled trial Retrospective cohort study
Age range 5 to 14 years 1 month to 13 years 3 months to 16 years 4 to 129 months
Countries included South Africa Uganda Zambia Belgium, Brazil, France, Germany,
Ireland, Italy, Portugal, Spain and UK
South Africa
Period of enrollment April 2009 to March 2011 May 2010 to
September 2013
January 1998 to July 2000 August 1998 to April 2013
Sample size (n) 557 365 130 9543
Intervention Abacavir, Lamivudine
and Efavirenz
Abacavir, Lamivudine
and NNRTI
Abacavir and Lamivudine ± Nelfinavir Abacavir, Lamivudine
and Lopinavir/ritonavir
or Efavirenz
Comparators Stavudine, Lamivudine
and Efavirenz
Zidovudine, Lamivudine
and NNRTI
Abacavir and Zidovudine ± Nelfinavir Stavudine, Lamivudine
and Lopinavir/ritonavir
or Efavirenz
Stavudine, Lamivudine
and NNRTI
Lamivudine and Stavudine ± Nelfinavir
Length of follow up Up to 24 months Up to 96 weeks Up to 5 years Up to 48 weeks
Funding sources United States Agency
for International
Development (USAID)
Medical Research
Council UK
European Commission, Medical Research
Council, the Istituto Superiore di Sanità,
Comunidad Autonoma de, Glaxo-Wellcome
and Agouron
National Institutes of Health
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Measures of treatment effect
We used Review Manager 5.3 [27] to manage the data
and to conduct analyses based on standard Cochrane
Collaboration methods [25]. We analysed results for
RCTs and observational studies separately. We calcu-
lated risk ratios (RR) for dichotomous data and planned
to use mean differences (MD) for continuous data.
However, none of the analysed data was of continuous
nature. We presented all results with 95 % confidence
intervals (CI).
Unit of analysis issues
Individual participants was the unit of analysis in each of
the included studies. The included RCTs had more than
two intervention arms and we only compared those that
are relevant and containing antiretroviral combinations
that are currently in use. We did not include the same
group of participants twice in the same meta-analysis.
We analysed outcome data that were available for two
or more time periods in separate meta-analyses.
Dealing with missing data
We contacted the authors of Musiime 2014 [28] in
September 2014 for clarity on non-disaggregated data
between the treatment naïve and treatment experienced
participants for outcomes such as adverse events, hyper-
sensitivity reaction and death but did not get any re-
sponse. Brennan 2014 [29] and Technau 2014 [15] were
also contacted in September 2014 to obtain unreported
data such as hypersensitivity reactions, CD4 cell counts
and adverse events. However, Technau 2014 responded
that we should use the available data while efforts would
be made to send other needed information to us but we
did not receive any of the requested additional informa-
tion till the end of the review.
Assessment of heterogeneity
We assessed heterogeneity between studies visually by
inspection of forest plots and statistically by means of the
Chi-square test where we pre-specified P < 0.1 to indicate
significant heterogeneity. We also quantified heterogeneity
with the I-squared (I2) test, where an I2 value of 50 % or
more was taken to indicate substantial heterogeneity [25].
Assessment of reporting biases
We planned to assess publication bias per outcome by
means of funnel plots where at least 10 studies have been
included. This review, however, did not have enough stud-
ies [25].
Data analysis
We carried out all meta-analyses with the random-effects
model because heterogeneity for the outcomes was sub-
stantial (I2 > 50 %); otherwise, we would have used the
fixed-effect model. For outcomes with only one study
where meta-analyses were not possible, a narrative synthe-
sis was done.
Subgroup analysis and investigation of heterogeneity
We planned to conduct subgroup analysis for different
types of antiretroviral agents (PIs and NNRTIs), study
settings (low, middle and high income countries) in the
intervention and control groups, and to compare the
intervention effects across different age groups (infants,
children and adolescents) but the available data did not
allow this.
Sensitivity analysis
We planned to conduct sensitivity analyses to assess the
effects of risk of bias and different statistical methods
employed in the meta-analyses for the primary out-
comes. However, due to the small number of included
studies such analyses were not practical.
Ethics
This study was a systematic review and meta-analysis of
existing literature and did not involve any human sub-
jects, therefore we did not require any approval from an
ethics committee.
Results
Figure 1 displays the process for searching and selecting
studies in accordance to the PRISMA guideline [30]. We
screened 2066 records and identified 11 studies as po-
tentially eligible.
The identified records were published in English, French,
Spanish, French and German languages. We screened the
non-English language abstracts by downloading their trans-
lated English version from the databases. After screening of
the full-text articles of the potentially eligible studies, only
four studies met the eligibility criteria. The rest were
excluded with reasons as shown in Table 2. No ongoing
studies were identified.
Table 2 Characteristics of excluded studies
Study Reasons for exclusion
Flynn 2014 [33] Non-disaggregation of the results into
different NRTI arms
Kline 1999 [34] Having abacavir in all the arms
Musiime 2013 [35] Measured outcomes are not of interest
Nahirya-Ntege 2011 [12] Having abacavir in all the arms
Neely 2013 [36] Having abacavir in all the arms
Penpact-1 2011 [37] Non-disaggregation of the results into
different NRTI arms
Sáez-Llorens 2001 [38] Previously treated children
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Included studies
We included two RCTs [28, 31, 32] and two analytical
cohort studies [14, 15, 29] with a total of 10,595 chil-
dren. The studies were conducted in different countries
across Europe, South America and sub-Saharan Africa.
Table 1 gives additional details.
Excluded studies
We excluded seven studies. Two studies were excluded
due to non-disaggregation of the results into different
NRTI arms [33, 34], three studies were excluded due to
having abacavir in all the intervention arms [12, 35, 36]
while another study was excluded because the partici-
pants were previously treated children [37]. A study
was also excluded because the outcomes were not of
interest [38]. Table 2 displays the reason for exclusion
per study.
Risk of bias and methodological quality assessment in
included studies
We judged Musiime 2004 to have an unclear risk of bias
because of incomplete statements concerning the par-
ticipant selection process. PENTA 2002had low risk of
selection bias as a result of adequate randomisation and
allocation concealment. PENTA 2002 and Musiime 2004
were judged to have low risk of bias for blinding because
the reported outcomes are objective and unlikely to be
influenced by lack of blinding. The two studies were
judged to have a low risk of attrition bias as they did not
have differential or large numbers of losses to follow-up
across the intervention arms. PENTA 2002 was judged
free of selective reporting while Musiime 2004 was un-
clear because the available article is a conference presen-
tation with limited information. The authors of PENTA
2002 reported having been sponsored by pharmaceutical
companies and governmental agencies but gave reassur-
ances that these organisations did not influenced the
trial. The authors of Musiime 2002 did not report in the
article the roles and involvement of the funders and we
were unsuccessful to obtain this information from them
via email. Brennan 2014 had three stars in the selection
domain, one star in the comparability domain and two
stars in the outcome domain while Technau 2014 had
three stars in selection domain, one star in comparability
domain and one star in the outcome domain. On a gen-
eral note the cohort studies perform fairly well in the
selection domain but poorly in the outcome domain.
Our judgements regarding the risk of bias in each
included RCT and methodological quality assessment for
cohort studies were presented in Tables 3 and 4.
Fig. 1 Flow diagram of the search and selection process for this review
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Effects of interventions
Comparison 1: Abacavir-containing cART regimens compared
to cART regimens containing zidovudine or stavudine (RCTs)
Virologic suppression Musiime 2004 defined virologic
suppression as <100 copies/mL concentration of HIV-1
RNA while PENTA 2002 defined virologic suppression
as <50 copies/ml. We found no significant difference
between abacavir and stavudine in virologic suppression:
2 RCTs, 326 participants with a RR of 1.28 (95 % CI
0.67–2.42). In Musiime 2004 where the participants be-
long to the low income countries / NNRTI subgroup, we
detected no difference between the two groups (RR 1.00;
95 % CI 0.88–1.13; n = 245). In PENTA 2002 where the
participants belong to high income countries/PI based
subgroup, children on abacavir containing regimen
were more likely to achieve virologic suppression than
those on stavudine based regimen (RR 1.82; 95 % CI
1.04–3.18; n = 81; I2 for heterogeneity = 81 %) (Fig. 2).
We detected no difference between abacavir and
zidovudine (2 RCTs, 325 participants) with a RR of
1.22 (95 % CI 0.55–2.72). Musiime 2004 reported less
likely virologic suppression in the abacavir group (RR
0.89; 95 % CI 0.80–0.99; n = 244). In PENTA 2002,
children on abacavir- containing regimen are likely to
achieve undetectable virologic suppression than those
on the zidovudine-containing regimen (RR 1.81; 95 %
CI 1.04–3.18; n = 81; I2 for heterogeneity = 88 %. The
quality of the evidence for this outcome was moder-
ate as shown in Table 5.
PENTA 2002 followed up study participants for
5 years. Those on abacavir- containing regimen likely
to achieve undetectable virologic suppression than
those on the zidovudine-containing regimen (RR 1.96;
95 % CI 1.11–3.34; n = 69).
CD4 cell count Only PENTA 2002 measured CD4 cell
count (absolute, cells/mL) from baseline to 48 weeks. The
study authors reported that for the abacavir group, there
was a median change of 272 (95 % CI 111–434; n = 47)
while for the other NRTI group the CD4 cell count was
182 (95 % CI 2–361; n = 36). We did not calculate an
effect size for this outcome because it was reported as
median change, therefore the quality of the evidence for
this outcome was not assessed.
Adverse events requiring treatment interruption or
switching regimens Only PENTA 2002 reported findings
on adverse events that led to treatment interruption or
switching of regimens. We detected no difference between
the intervention and control groups (RR 2.41; 95 % CI
0.10–57.52; n = 81). The quality of the evidence for this
outcome was considered low.
Hypersensitivity reaction Musiime 2004 reported the
findings of both treatment naïve and experienced cases
together without disaggregation. Abacavir had no case of
hypersensitivity reaction but in the control groups there
were reactions (abacavir = 0/164 = 0 %, zidovudine = 1/
158 = 0.63 %, stavudine = 2/156 = 1.28 %; n = 478). We
did not calculate an effect size for this outcome because
we could not obtain data for only the treatment naïve
participants. Therefore the quality of the evidence for
this outcome was not assessed. PENTA 2002 reported a
case of abacavir hypersensitivity reaction in child on aba-
cavir/zidovudine/nelfinavir combination. Both trials did
not give any specific definition of abacavir hypersensitiv-
ity reaction and HLA-B*5701 screening test was not
carried out on any of the participants.
Death Musiime 2004 reported death as an outcome for
both treatment naïve and experienced participants with-
out disaggregating the two groups (n = 478). The authors
reported 19 deaths with no significant difference across the
three arms of the study without specifying the numbers for
Table 3 Risk of bias in included RCTs
Random
sequence
generation
Allocation concealment Blinding of
participants
and care providers
Blinding of
outcome
assessors
Incomplete
outcome data
Selective
reporting
Other bias
Musiime 2014 [28] Unclear Unclear Low Low Low Unclear Unclear
PENTA 2002 [31] Low Low Low Low Low Low Low
Table 4 Quality assessment of cohort studies
Quality evaluation Brennan
2014 [29]
Technau
2014 yy
Representativeness of the exposed cohort * *
Selection of the non-exposed cohort * *
Ascertainment of exposure - -
Demonstration that outcome of interest
was not present at the start of the study
* *
Comparability * *
Assessment of outcomes - *
Was follow up long enough for outcomes to occur * -
Adequacy of follow up of cohorts * -
Total score 6 5
Table 4 shows the quality assessment of each of the included cohort studies
using the Newcastle - Ottawa Scale. Each item can receive 1 star (*), except for
Comparability that can receive 2 stars. The total number of stars represents
the score, which demonstrates the quality of the study
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Fig. 2 Forest plots of abacavir-containing regimen versus other nucleoside reversible transcriptase inhibitors (RCTs)
Table 5 Summary of findings table for abacavir-containing cART regimens compared to cART regimens containing zidovudine or
stavudine (RCTs)
Outcomes Illustrative comparative risks* (95 % CI) Relative
effect
(95 %
CI)
No of
Participants
(studies)
Quality of
the
evidence
(GRADE)
Assumed risk Corresponding risk
AZT or d4T - containing combination
antiretroviral regimens
ABC- containing combination
antiretroviral regimens
Virologic suppression - ABC versus d4T
(VL < 50–100 copies/ml)
688 per 1000 881 per 1000 RR 1.28 326 ⊕⊕⊕⊝
Follow-up: mean 48 weeks (461–1000) (0.67–
2.42
(2 studies) moderatea
Adverse events 0 per 1000 0 per 1000 RR 2.41 81 ⊕⊕⊝⊝
Follow-up: mean 48 weeks (0–0) (0.1–
57.52)
(1 study) lowa,b
Death 0 per 1000 0 per 1000 RR 2.41 81 ⊕⊕⊝⊝
Follow-up: mean 48 weeks (0–0) (0.1–
57.52)
(1 study) lowa,b
a Estimate of effect has a wide conference interval, including both a reduction and increase of effects
b One study with a small number of participants
* The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI)
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each arms of intervention. PENTA 2002 showed no differ-
ence between abacavir and zidovudine groups (RR 2.41;
95 % CI 0.10–57.52; n = 81). The quality of the evidence for
this outcome was low as shown in Table 5.
Myocardial infarction and other cardiovascular events
None of the studies measured myocardial infarction and
other cardiovascular outcomes.
Comparison 2: Abacavir-containing cART regimens compared
to cART regimens containing zidovudine or stavudine (cohort
studies)
Virologic suppression For the included cohort studies,
only Technau 2014 reported findings on virologic sup-
pression. The study reported < 50 copies/mL as the low-
est value concentration of HIV-1 RNA non-detectable
level. We found abacavir regimen to be less likely to
achieve virologic suppression than stavudine regimen
(RR 0.79; 95 % CI 0.67–0.92; n = 2165) (Fig. 3). The
quality of the evidence for this outcome was low as
shown in Table 6.
Virologic failure Brennan 2014 defined virologic failure
as the proportion of participants with a viral load of
more than 400 copies/mL after 24 months of treatment.
We detected no difference in virologic failure between
abacavir regimen and stavudine regimen (RR 1.01; 95 %
CI 0.73–1.39; n = 557). The quality of the evidence for
this outcome was considered low.
Death For Brennan 2014 we detected no difference
between abacavir and stavudine regimen at 24 months
follow-up period (RR 0.72; 95 % CI 0.27–1.92; n = 557).
Fig. 3 Forest plots of abacavir-containing regimen versus other nucleoside reverse transcriptase inhibitors (cohort studies)
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The quality of the evidence for this outcome was
judged low.
Discussion
The participants of the included studies received
twelve different drug combinations. Comparing effects
of the interventions across the individual studies was
limited due to different study designs, important out-
comes not measured in all studies, statistical hetero-
geneity between studies, and the multiplicity of the
interventions. Different drug combinations such as
NRTI backbones like abacavir/lamivudine, zidovudine/
lamivudine and stavudine/lamivudine; and in using
efavirenz, lopinavir/ritonavir, nevirapine, and nelfinavir
as the third drug; plus the use of double or triple
ART combinations accounted for the multiplicity na-
ture of the interventions.
The included studies compared abacavir/lamivudine to
stavudine/lamivudine or zidovudine/lamivudine as double
or triple drug regimens and used NNRTIs or PIs as a third
drug. This potentially masked the head-to-head compari-
son of abacavir to stavudine or zidovudine. The PENTA
2002 study compared abacavir/lamivudine, zidovudine/
lamivudine and abacavir/zidovudine with a PI (nelfinavir)
as the third drug [31, 32]. However, only some symptom
free participants were given the PI while others were on
two drug regimens. Nelfinavir is found to be less effica-
cious than current PI regimens such as ritonavir-boosted
PIs, both in tolerability and virologic suppression, and it is
no longer a component of recommended ART regimen
for children or adults [39]. The use of abacavir/zidovudine
double therapy combination is no longer encouraged in
the management of HIV infected children [4].
Findings across studies contrasted each other for the
outcome virologic suppression as Musiime [28] showed
no difference between abacavir-containing regimen and
that of the stavudine-containing regimen. The same
study found abacavir regimen to be less efficacious when
compared with those containing zidovudine for up to
48 weeks of treatment. However, PENTA [32] findings
showed that abacavir- containing regimen is marginally
more efficacious when compared to others at 48 weeks.
The cohort study by Technau and colleagues found that
abacavir-containing regimens had lesser virologic effi-
cacy in comparison to stavudine regimens for both lopi-
navir/ ritonavir and efavirenz based combinations [15].
Brennan 2014, on the other hand, found no difference in
virologic failure between abacavir and stavudine regi-
mens [29]. There was also no difference in incidence of
death in the intervention and control groups in the
PENTA 2002 and Brennan 2014 studies. Musiime and
colleagues (2014) did not observe any abacavir-related
hypersensitivity reactions in their trial. They found
abacavir-containing regimen was well tolerated and had
little safety concerns in terms of adverse events that war-
rants discontinuation [28]. PENTA 2002 reported a case
of reaction to abacavir and three other cases that were
suspected to be abacavir hypersensitivity reactions [14].
None of the included studies reported on myocardial
infarction and other cardiovascular events.
Of all the included studies, the most direct compari-
sons between abacavir and other NRTIs in children was
by the Musiime 2014 trial which used currently recom-
mended regimens. The findings showed that treatment
naïve children did well on abacavir, zidovudine and stav-
udine based triple regimens, with low toxicity for the
three regimens and high viral load suppression up at
Table 6 Summary of findings table for abacavir-containing cART regimens compared to cART regimens containing zidovudine or
stavudine (cohort studies)
Outcomes Illustrative comparative risks* (95 % CI) Relative
effect
(95 %
CI)
No of
Participants
(studies)
Quality of
the
evidence
(GRADE)
Assumed risk Corresponding risk
AZT or d4T - containing combination antiretroviral
regimens
ABC -containing
combination antiretroviral
regimens
Virologic suppression - Lopinavir/
ritonavir based (VL < 50 copies/
ml)
516 per 1000 408 per 1000 RR 0.79 2165 ⊕⊕⊝⊝
Follow-up: mean 48 weeks (346–475) (0.67–
0.92)
(1 study) low
Virologic failure 211 per 1000 213 per 1000 RR 1.01 557 ⊕⊕⊝⊝
Follow-up: mean 24 months (154–294) (0.73–
1.39)
(1 study) low
Death 35 per 1000 25 per 1000 RR 0.72 557 ⊕⊕⊝⊝
Follow-up: mean 24 months (9–67) (0.27–
1.92)
(1 study) low
* The corresponding risk (and its 95% confidence interval) is based on the assumed risk in thecomparison group and the relative effect of the intervention (and its
95% CI)
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96 weeks follow up period. Musiime 2014 findings also
support the ARROW (AntiRetroviral Research fOr Watoto)
study report of low incidence of abacavir hypersensitivity
reaction in African children. ARROW was an open-label
randomised evaluation of induction-maintenance and mon-
itoring strategies in symptomatic HIV-infected infants and
children initiating abacavir and lamivudine plus nevirapine
or efavirenz in Uganda and Zimbabwe. The low incidence
of abacavir hypersensitivity reaction among the children
was attributed to lower prevalence of HLA-B*5701 in
African populations [12]. Brennan 2014 concluded that
although abacavir and stavudine regimens had comparable
viral load status by 24-months on treatment, participants
on stavudine had higher risk of death and poorer immune
response outcomes [29].
A systematic review and meta-regression analysis by
Hill and Sawyer suggests lower efficacy for first-line use
of abacavir/lamivudine NRTI backbone with boosted PIs
relative to tenofovir/ emtricitabine in adults. There were
also assumptions that the effect might have been con-
founded by differences between the trials in terms of
their baseline characteristics, patient management and
adherence [40]. Another systematic review and meta-
analysis, by Cruciani et al., assessed treatment naïve and
treatment experienced HIV-infected adult patients and
found that abacavir-containing regimens and tenofovir-
containing regimens have similar virological efficacy.
Adverse events requiring discontinuation of treatment
were reported to occur slightly more frequently in aba-
cavir recipients but the difference was not statistically
significant [41]. However, none of the intervention arms
of the included studies of this systematic review has
tenofovir or emtricitabine NRTI backbone to make a
good comparison.
Overall completeness and applicability of evidence
The included studies in this review have a variety of lim-
itations. PENTA 2002 was a small (n = 81), open-label
trial while for Musiime 2014 we only have a conference
presentation to provide information about the study.
Brennan 2014 was also a conference presentation with
numerous issues that needed clarification, while Tech-
nau 2014 presented findings only on virologic suppres-
sion. Technau 2014 had a considerable proportion of the
participants (44 %) not doing viral load testing during
the 12 month window period (probably due to the fact
that abacavir was recently adopted for use thereby hav-
ing fewer data available unlike stavudine). There is also
the possibility of selection bias if viral load testing was
done in children who appear more healthy [14, 15].
Apart from PENTA 2002 that had a 5 year follow up,
the other studies had rather shorter follow up periods
which limits the confidence we can have in the findings.
Quality of the evidence
The reporting of the included studies was largely inad-
equate and this necessitated contacting the trial authors
to try and obtain the required information. Unfortu-
nately we were unsuccessful in this regard for the studies
Musiime 2014, Brennan 2014, Flynn 2014 and Technau
2014. The lead author of Technau 2014 advised that we
should continue using the available data while an author
from Flynn 2014 referred us to the sponsors. The spon-
sors, however, were reluctant to share the requested
data. The virologic suppression outcome data of treat-
ment naïve and experienced participants in the Musiime
2014 study was not disaggregated but we estimated the
total number of participants for each arm by using the
reported randomisation ratio of 1:1:1 to calculate the
total number for each arm for the treatment naïve par-
ticipants. We downgraded the evidence from the RCTs
for imprecision because the estimate of effect has a wide
conference interval, including both a reduction and
increase of effects; and did not upgrade any of the
evidence from the cohort studies. Significant heterogen-
eity (I2 = 81 % and 88 %) is probably due to the multipli-
city nature of the antiretroviral combinations.
The NOS quality rating for the two observational
studies was good for the Selection domains, fair for the
Comparability domain and fair for the Outcome domain
[42]. The biggest limitation in the cohort studies was the
low uptake viral load testing between 65 and 75 % at 6
and 12 months with larger proportion of children on
stavudine doing the viral load testing than those on aba-
cavir [15].
Potential biases in the review process
We minimised the biases in the review process by having
a comprehensive search strategy across a number of
databases and other sources, as well as not limiting the
search to studies in specific languages. We were unable
to assess the likelihood of publication bias due to having
only four included studies.
Conclusions
Implications for practice
Abacavir-containing cART regimens remain a viable
option as the first-line treatment for HIV infected
children and adolescents as recommended by the
WHO [4]. In this review we found that abacavir in
combination with other classes of antiretroviral medi-
cine is not different in efficacy and safety when com-
pared to stavudine and zidovudine, for both the early
stage and long term treatment. For this reason, the
current clinical guideline from the WHO that recom-
mends abacavir, stavudine or zidovudine for treating chil-
dren and adolescents based on the patients’ profile in
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terms of toxicity and non-availability of other preferred
regimens should still stand.
Implications for policy making
The quality of the evidence available from the included
studies based on GRADE criteria was generally low for
the analysed outcomes except in the case of virologic
suppression for the RCTs which was moderate. The
findings of this study are not suggestive of any major
change in the existing treatment policy.
Implications for research
There is a need for adequately powered and well planned
RCTs of abacavir-containing cART regimens that are
reported according to the CONsolidated Standards of
Reporting Trials (CONSORT) guidelines [43]. These stud-
ies should be designed to generate high-quality evidence
in different settings. The focus should be on virologic
response, adverse events (including hypersensitivity reac-
tions and cardiovascular events) and mortality. Harm may
also be researched with analytical cohort studies if more
feasible.
Further research on abacavir-containing cART regimen
should also be geared towards defining the subgroup of HIV
infected children and adolescents for whom this regimen will
be most beneficial, such as different age groups, co-
morbidities and different dosages and combinations of
regimens. Common comparator regimens such as those con-
taining zidovudine, tenofovir and emtricitabine NRTI back-
bones should be included in the RCTs. The research studies
should ideally have a follow-up duration of at least 5 years.
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